1. Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. Issue 12 (4th September 2021) Authors: Forsberg, Peter A.; Rossi, Adriana C.; Boyer, Angelique; Pearse, Roger N.; Pekle, Karen A.; Jayabalan, David; Lakritz, Stephanie; Flicker, Kari; Ribadeneyra, Drew; Liotta, Brielle; Ely, Scott; Boussi, Leora; Allan, John N.; Coleman, Morton; Niesvizky, Ruben; Mark, Tomer M. Journal: American journal of hematology Issue: Volume 96:Issue 12(2021) Page Start: 1554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Issue 5 (25th February 2019) Authors: Forsberg, Peter A.; Rossi, Adriana C.; Boyer, Angelique; Tegnestam, Linda; Pearse, Roger N.; Perry, Arthur; Pekle, Karen A.; Jayabalan, David; Ely, Scott; Boussi, Leora; Sherbenou, Daniel W.; Williams, Colt; Allan, John N.; Coleman, Morton; Niesvizky, Ruben; Mark, Tomer M. Journal: American journal of hematology Issue: Volume 94:Issue 5(2019:May) Page Start: 539 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗